Market Overview

UPDATE: Bloom Burton Downgrades Theratechnologies to Sell, Lowers PT

Related THER
Stocks Hitting 52-Week Lows
Winning Trades Based on Analyst Ratings for June 25

In a research comment published earlier today, Bloom Burton & Co. Inc. downgraded its rating for Theratechnologies Inc. (NASDAQ: THER) from Hold to Sell, and lowered its price target from $2.50 to $0.75.

Bloom Burton went on to say “While the stock has already reacted to this negative news, we now see no reason to hold THER stock. THER has a cash balance of $28.5 million (Feb 28, 2012) or $0.47/share, which is steadily declining. We forecast peak sales of Egrifta of $80-100 million with a 12-13% royalty. If we add in expected manufacturing sales, we estimate total Egrifta royalty + revenues to THER of about $25 million in F2013 ($0.40/share). In addition, as a result of this latest news, we could see further cost cutting measures at THER. We believe there are no meaningful milestones to drive value in the stock in the near term.”

Theratechnologies Inc. closed on Friday at $0.73.

Latest Ratings for THER

Jun 2012Bloom Burton & Co.DowngradesHoldSell

View More Analyst Ratings for THER
View the Latest Analyst Ratings

Posted-In: Bloom Burton & Co.Analyst Color Downgrades Price Target Analyst Ratings


Related Articles (THER)

View Comments and Join the Discussion!

Partner Center